Our previous results showed that combination therapy, composed of EGFR (gefitinib or lapatinib) and MET (foretinib) inhibitors, was much more effective against melanoma cells in a comparison to a monotherapy (Dratkiewicz et al., 2018). The gene discussed is EGFR; the disease is melanoma.